Humanoid, Inc. (HERB)

OTCMKTS · Delayed Price · Currency is USD
0.0470
0.00 (0.00%)
Jan 21, 2026, 4:00 PM EST
-46.59%
Market Cap7.39M
Revenue (ttm)24.15M
Net Income (ttm)8.07M
Shares Out157.17M
EPS (ttm)0.05
PE Ratio0.92
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume7,404
Open0.0470
Previous Close0.0470
Day's Range0.0470 - 0.0470
52-Week Range0.0150 - 0.0990
Beta0.65
RSI53.63
Earnings DateFeb 19, 2026

About Humanoid

Humanoid, Inc., through its subsidiaries, designs, develops, manufactures, and markets farming and sideline products; chemical materials and products; textiles; construction materials; and livestock and poultry products. It cultivates, processes, markets, and distributes various food and agro-byproducts; and manufactures and supplies nutrition and healthcare products. The company’s products portfolio includes cotton and wool, sorghum, grains, barley, soybean, alfalfa, corn, and wheat; onions, beets, lupin, bell peppers, potato, peas, carrots, a... [Read more]

Industry Farm Products
Founded 1998
Employees 255
Stock Exchange OTCMKTS
Ticker Symbol HERB
Full Company Profile

Financial Performance

In 2024, Humanoid's revenue was $24.15 million, an increase of 14.25% compared to the previous year's $21.14 million. Earnings were $8.07 million, an increase of 15.00%.

Financial Statements

News

Yasheng Group Reports Financial Results for the First Quarter of 2023:

Enters into Joint Venture to Commence Gold Mining in Arizona with Operations to Commence this Month: Awaits Final Preferred Dividend Decision of FINRA Enters into Joint Venture to Commence Gold Mining...

2 years ago - GlobeNewsWire

Rare Earth Elements Collected from Wastewater Utilizing Cyanobacteria Now Patent Pending

SAN JOSE, March 15, 2023 (GLOBE NEWSWIRE) -- SAN JOSE, CA--(March 15, 2023) - Yasheng Group, (OTC: HERB), an agricultural and biotech company with U.S. headquarters in San Jose, California today annou...

3 years ago - GlobeNewsWire

Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders

Begins Raising Capital for our Subsidiary, Jove Pharmaceutics In Order to Bring Next Generation Cancer Curing Cell Therapeutics to Market Begins Raising Capital for our Subsidiary, Jove Pharmaceutics ...

3 years ago - GlobeNewsWire

Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development

San Jose, California, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development

3 years ago - GlobeNewsWire